PL373568A1 - Zastosowanie inhibitorów kinazy I kappa B w leczeniu bólu - Google Patents

Zastosowanie inhibitorów kinazy I kappa B w leczeniu bólu

Info

Publication number
PL373568A1
PL373568A1 PL03373568A PL37356803A PL373568A1 PL 373568 A1 PL373568 A1 PL 373568A1 PL 03373568 A PL03373568 A PL 03373568A PL 37356803 A PL37356803 A PL 37356803A PL 373568 A1 PL373568 A1 PL 373568A1
Authority
PL
Poland
Prior art keywords
kappa
pain
treatment
kinase inhibitors
kinase
Prior art date
Application number
PL03373568A
Other languages
English (en)
Other versions
PL212356B1 (pl
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of PL373568A1 publication Critical patent/PL373568A1/pl
Publication of PL212356B1 publication Critical patent/PL212356B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL373568A 2002-08-17 2003-08-05 Zastosowanie inhibitorów kinazy I K B PL212356B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie

Publications (2)

Publication Number Publication Date
PL373568A1 true PL373568A1 (pl) 2005-09-05
PL212356B1 PL212356B1 (pl) 2012-09-28

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373568A PL212356B1 (pl) 2002-08-17 2003-08-05 Zastosowanie inhibitorów kinazy I K B

Country Status (33)

Country Link
EP (1) EP1531819B1 (pl)
JP (1) JP4504811B2 (pl)
KR (2) KR20110135428A (pl)
CN (1) CN100398107C (pl)
AR (1) AR043045A1 (pl)
AT (1) ATE418336T1 (pl)
AU (1) AU2003271555B2 (pl)
BR (1) BR0313555A (pl)
CA (1) CA2495455C (pl)
CO (1) CO5690585A2 (pl)
CR (1) CR7716A (pl)
CY (1) CY1108874T1 (pl)
DE (2) DE10237723A1 (pl)
DK (1) DK1531819T3 (pl)
EC (1) ECSP055609A (pl)
ES (1) ES2320118T3 (pl)
HR (1) HRP20050041B1 (pl)
IL (1) IL166780A (pl)
MA (1) MA27334A1 (pl)
MX (1) MXPA05001218A (pl)
MY (1) MY138059A (pl)
NO (1) NO334309B1 (pl)
OA (1) OA12907A (pl)
PL (1) PL212356B1 (pl)
PT (1) PT1531819E (pl)
RS (1) RS51878B (pl)
RU (1) RU2320338C2 (pl)
SI (1) SI1531819T1 (pl)
TN (1) TNSN05044A1 (pl)
TW (1) TWI325782B (pl)
UA (1) UA80837C2 (pl)
WO (1) WO2004022057A1 (pl)
ZA (1) ZA200500323B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201242962A (en) * 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104105483B (zh) * 2011-12-06 2017-03-22 赛诺菲 2‑(2‑甲基氨基‑嘧啶‑4‑基)‑1h‑吲哚‑5‑羧酸[(s)‑1‑氨甲酰基‑2‑(苯基‑嘧啶‑2‑基‑氨基)‑乙基]‑酰胺的晶体形式
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AU2015283052B2 (en) * 2014-07-03 2020-01-02 Sanofi 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid ((s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl)-amide for use in the treatment of pain associated to osteoarthritis
WO2020016749A2 (en) 2018-07-16 2020-01-23 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL206826B1 (pl) * 1999-06-23 2010-09-30 Sanofi Aventis Deutschland Podstawione benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
AU2003271555A1 (en) 2004-03-29
SI1531819T1 (sl) 2009-06-30
CR7716A (es) 2008-11-25
CA2495455A1 (en) 2004-03-18
DE10237723A1 (de) 2004-07-08
MXPA05001218A (es) 2005-05-16
WO2004022057A1 (de) 2004-03-18
EP1531819A1 (de) 2005-05-25
DK1531819T3 (da) 2009-04-20
KR20110135428A (ko) 2011-12-16
CA2495455C (en) 2011-01-11
RS20050070A (sr) 2007-06-04
TW200417370A (en) 2004-09-16
CO5690585A2 (es) 2006-10-31
NO20051339L (no) 2005-05-03
TNSN05044A1 (en) 2007-05-14
RU2320338C2 (ru) 2008-03-27
OA12907A (en) 2006-10-13
ATE418336T1 (de) 2009-01-15
IL166780A0 (en) 2006-01-15
CY1108874T1 (el) 2014-07-02
HK1079426A1 (en) 2006-04-07
RU2005107419A (ru) 2005-08-10
TWI325782B (en) 2010-06-11
JP4504811B2 (ja) 2010-07-14
ZA200500323B (en) 2006-02-22
HRP20050041A2 (hr) 2006-04-30
PL212356B1 (pl) 2012-09-28
CN100398107C (zh) 2008-07-02
HRP20050041B1 (hr) 2013-07-31
KR20050058339A (ko) 2005-06-16
DE50310980D1 (de) 2009-02-05
KR101119845B1 (ko) 2012-02-28
AU2003271555B2 (en) 2009-03-26
IL166780A (en) 2011-11-30
CN1674899A (zh) 2005-09-28
AR043045A1 (es) 2005-07-13
UA80837C2 (uk) 2007-11-12
RS51878B (sr) 2012-02-29
MY138059A (en) 2009-04-30
BR0313555A (pt) 2005-07-12
MA27334A1 (fr) 2005-05-02
JP2005539053A (ja) 2005-12-22
EP1531819B1 (de) 2008-12-24
ECSP055609A (es) 2005-04-18
PT1531819E (pt) 2009-02-18
NO334309B1 (no) 2014-02-03
ES2320118T3 (es) 2009-05-19

Similar Documents

Publication Publication Date Title
PT1531819E (pt) Utilização de inibidores da i capa b cinase na terapia da dor
IL209352A0 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0401605A3 (en) Integrin inhibitors for the treatment of eye diseases
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0211295D0 (en) Treatment of pain
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
GB2410744B (en) Kinase inhibitors for the treatment of disease
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
HUP0402664A3 (en) 2-indanylamino derivatives for the therapy of chronic pain
PL370839A1 (pl) Zastosowanie inhibitorów pompy protonowej do leczenia zaburzeń dróg oddechowych
PL370840A1 (pl) Zastosowanie inhibitorów pompy protonowej do leczenia bólów w klatce piersiowej nie na tle sercowym
GB0325957D0 (en) The treatment of pain
GB0216978D0 (en) The treatment of pain
GB0213870D0 (en) The treatment of pain conditions

Legal Events

Date Code Title Description
RECP Rectifications of patent specification